You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Express Scripts
Medtronic
Moodys
McKinsey

Last Updated: April 8, 2020

DrugPatentWatch Database Preview

Litigation Details for Teva Pharmaceuticals USA, Inc. v. Mylan Pharmaceuticals Inc. (S.D.N.Y. 2009)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Teva Pharmaceuticals USA, Inc. v. Mylan Pharmaceuticals Inc. (S.D.N.Y. 2009)

Docket   Start Trial Date Filed 2009-10-16
Court District Court, S.D. New York Date Terminated 2012-07-24
Cause 35:271 Patent Infringement Assigned To William H. Pauley III
Jury Demand None Referred To
Parties MYLAN INC.; MYLAN PHARMACEUTICALS INC.; NATCO PHARMA LTD.; TEVA NEUROSCIENCE, INC.; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA, INC.; YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Patents 10,086,010; 10,086,011; 5,981,589; 6,054,430; 6,342,476; 6,362,161; 6,620,847; 6,939,539; 7,199,098; 9,000,021
Attorneys Alfonso Nathaniel Cornish , II; Andrew Levine; Anthony H. Cataldo; Beth D. Jacob; Brandon Michael White; Carolyn Anne Blessing; Colin Gene Sandercock; Daryl L Wiesen; David E. Jones; David L. Anstaett; David M. Hashmall; Dennis Cecil Hopkins; Elizabeth J. Holland; John Singleton Skilton; John T. Bennett; Joseph B. Crystal; Kenneth Nji Ebie; Melody K. Glazer; Nicholas Groombridge; Nicholas K Mitrokostas; Patrice Polyxene Jean; Patricia Young; Ricardo Solano , Jr; Sarah C. Walkenhorst; Shannon M Bloodworth; Steven Jeffrey Lee; William G. James , II; William Mcginley Jay
Firms Friedman Kaplan Seiler & Adelman LLP; Friedman Kaplan Seiler & Adelman LLP (NYC); Gibson, Dunn & Crutcher, LLP (DC); Goodwin Procter, LLP (Boston); Goodwin Procter, LLP (NYC), the New York Times Building; Kenyon & Kenyon LLP; Perkins Coie LLP; Perkins Coie LLP (DC); Perkins Coie LLP (WI); Perkins Coie, L.L.P (WISC); Perkins Coie, L.L.P. (WISC); Schiff Hardin LLP; Teva Pharamaceuticals USA, Inc.; Weil, Gotshal & Manges LLP (NYC)
Link to Docket External link to docket
Small Molecule Drugs cited in Teva Pharmaceuticals USA, Inc. v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Teva Pharmaceuticals USA, Inc. v. Mylan Pharmaceuticals Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Teva Pharmaceuticals USA, Inc. v. Mylan Pharmaceuticals Inc. (S.D.N.Y. 2009)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 Complaint COUNT V FOR INFRINGEMENT OF UNITED STATES PATENT NO. 5,981.589 47. The allegations of paragraphs 1-46 …JUDGMENT OF INFRINGEMENT OF UNITED STATES PATENT NO. 5,981,589 76. The allegations of paragraphs 1-75 …098 patent. 16. Teva Ltd. is the exclusive licensee of the ’098 patent l7. United States Patent No. …539 patent. 18. Teva Ltd. is the exclusive licensee of the ’539 patent. 19. United States Patent No.…430 patent. 20. Teva Ltd. is the exclusive licensee of the ’430 patent. 21. United States Patent No. External link to document
0000-00-00 201 LIMITATIONS IN CLAIMS 12, 23, 30, AND 31 OF U.S. PATENT NO. 6,939,539: It is hereby Stipulated and Agreed by and…limitations of Claim 12, 23, 30 and 31 of U.S. Patent No. 6,939,539. Plaintiff will not call Dr. Arthur H. Kibbe…limitations in Claim 12, 23, 30 and 31 of U.S. Patent No. 6,939,539; and Mylan will have the right to argue …2009 24 July 2012 1:09-cv-08824 830 Patent None District Court, S.D. New External link to document
2011-10-04 205 the 4.64, 1.57, 3.65 and 1, 10 you get to 10.86. 11 Before we were looking at it on … in view of the '550 patent as a basis 25 for invalidating the patents in suit. And I think…considered by the Patent Office over years and years of 14 prosecution and the Patent Office decided …molar ratio is why Mylan's patent 3 does not infringe on the patents in suit. 4 So…this case 4 obtained the '287 patent in 2004. This patent is not asserted 5 here, your Honor External link to document
2011-10-04 209 simply takes 4.64 alanines and 9 divides by 10.86, so 10.86 is the denominator and then to 10 convert…Weizmann Institute's '550 patent? 5 A. The '550 patent relates to polymers of that type… in the '550 Weizmann Institute patent? 11 A. The patent describes polymers that have alanine…when was that patent issued, sir? 15 A. November 19, 1974. 16 Q. Now, that patent, it also describes…concerning the '808 patent, correct? 23 A. I testified about the '808 patent. 24 Q. Are you External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Baxter
Mallinckrodt
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.